Genomed S.A. Stock: price and insider trades · Poland

Genomed S.A. is a Health Care company. Its directors and officers file their transactions with KNF. The last twelve months, up to 23 October 2026, brought 25 filings signed by 2 insiders.

The record shows 1 purchase on the open market worth €2,332, made by 1 insider, against 1 sale worth €4,365 by 1 insider. Sales outweigh purchases by €2,033. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Among those who bought: 1 senior executive. The largest single trade was a sale of €4,365, published on 18 May 2026.

The last purchase on record was published on 18 May 2026, which is 158 days ago.

Across the 554 companies tracked on its exchange, the median is 3 filings; at 25 filings, this issuer sits above that mark. Over the whole record (from 2025), the tally stands at 1 purchase and 1 sale.

In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. These figures are compiled from regulatory filings published by KNF. They describe what insiders did and are not a recommendation.